

Owen J T Mccarty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2146037/publications.pdf>

Version: 2024-02-01

146
papers

5,371
citations

71102

41
h-index

98798

67
g-index

146
all docs

146
docs citations

146
times ranked

5796
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. <i>Platelets</i> , 2022, 33, 66-72.	2.3	18
2	Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. <i>Platelets</i> , 2022, 33, 404-415.	2.3	13
3	Severe thrombocytopenia in adults undergoing extracorporeal membrane oxygenation is predictive of thrombosis. <i>Platelets</i> , 2022, 33, 570-576.	2.3	10
4	Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains. <i>Blood Advances</i> , 2022, 6, 3142-3154.	5.2	14
5	Chronic edible dosing of δ^9 -tetrahydrocannabinol (THC) in nonhuman primates reduces systemic platelet activity and function. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C370-C381.	4.6	4
6	Irreversible alteration of extracellular vesicle and cell-free messenger RNA profiles in human plasma associated with blood processing and storage. <i>Scientific Reports</i> , 2022, 12, 2099.	3.3	11
7	Effects of ex vivo blood anticoagulation and preanalytical processing time on the proteome content of platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1437-1450.	3.8	12
8	Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1496-1506.	3.8	5
9	Revised model of the tissue factor pathway of thrombin generation: Role of the feedback activation of FXI. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1350-1363.	3.8	14
10	Ibrutinib Inhibits BMX-Dependent Endothelial VCAM-1 Expression In Vitro and Pro-Atherosclerotic Endothelial Activation and Platelet Adhesion In Vivo. <i>Cellular and Molecular Bioengineering</i> , 2022, 15, 231-243.	2.1	5
11	Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2035-2045.	3.8	8
12	The basement membrane protein nidogen-1 supports platelet adhesion and activation. <i>Platelets</i> , 2021, 32, 424-428.	2.3	9
13	Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 161-175.	2.1	12
14	Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. <i>ASAIO Journal</i> , 2021, 67, 290-296.	1.6	115
15	Heparin Resistance Is Common in Patients Undergoing Extracorporeal Membrane Oxygenation but Is Not Associated with Worse Clinical Outcomes. <i>ASAIO Journal</i> , 2021, 67, 899-906.	1.6	9
16	Thrombin generation and activity in multiple sclerosis. <i>Metabolic Brain Disease</i> , 2021, 36, 407-420.	2.9	9
17	Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1001-1017.	3.8	26
18	Factor XII plays a pathogenic role in organ failure and death in baboons challenged with <i>Staphylococcus aureus</i> . <i>Blood</i> , 2021, 138, 178-189.	1.4	15

#	ARTICLE	IF	CITATIONS
19	Role of platelets in regulating activated coagulation factor XI activity. American Journal of Physiology - Cell Physiology, 2021, 320, C365-C374.	4.6	12
20	Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and disease. Small GTPases, 2021, 12, 440-457.	1.6	7
21	Cross-Talk between the Complement Pathway and the Contact Activation System of Coagulation: Activated Factor XI Neutralizes Complement Factor H. Journal of Immunology, 2021, 206, 1784-1792.	0.8	24
22	Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. American Journal of Physiology - Cell Physiology, 2021, 320, C902-C915.	4.6	22
23	Aspirin and antiplatelet treatments in cancer. Blood, 2021, 137, 3201-3211.	1.4	49
24	The contact activation inhibitor ABO23 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood, 2021, 138, 2173-2184.	1.4	56
25	The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor- κ B and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions. Frontiers in Immunology, 2021, 12, 729951.	4.8	12
26	Innovation, entrepreneurship, promotion, and tenure. Science, 2021, 373, 1312-1314.	12.6	10
27	Droplet Microfluidics with Reagent Micromixing for Investigating Intrinsic Platelet Functionality. Cellular and Molecular Bioengineering, 2021, 14, 223-230.	2.1	2
28	Platelet integrin activation surfs the calcium waves. Platelets, 2021, 32, 437-439.	2.3	2
29	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. Blood, 2021, 138, 441-441.	1.4	0
30	Assessment of neonatal, cord, and adult platelet granule trafficking and secretion. Platelets, 2020, 31, 68-78.	2.3	17
31	Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. Journal of Thrombosis and Haemostasis, 2020, 18, 180-190.	3.8	20
32	Evaluation of the Effect of Crosslinking Method of Poly(Vinyl Alcohol) Hydrogels on Thrombogenicity. Cardiovascular Engineering and Technology, 2020, 11, 448-455.	1.6	9
33	A Theme Series on Emerging Technologies for Use in the Study, Diagnosis and Treatment of Patients with COVID-19. Cellular and Molecular Bioengineering, 2020, 13, 247-248.	2.1	0
34	Design of a Microfluidic Bleeding Chip to Evaluate Antithrombotic Agents for Use in COVID-19 Patients. Cellular and Molecular Bioengineering, 2020, 13, 331-339.	2.1	6
35	Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs. Blood, 2020, 136, 2346-2358.	1.4	53
36	Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 205-216.	2.3	29

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 179-187.	2.1	2
38	The contact activation system as a potential therapeutic target in patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 500-505.	2.3	33
39	The protein C activator AB002 rapidly interrupts thrombus development in baboons. <i>Blood</i> , 2020, 135, 689-699.	1.4	8
40	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Blood</i> , 2020, 136, 23-24.	1.4	2
41	The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 502-508.	2.7	49
42	The contact pathway and sepsis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 331-339.	2.3	28
43	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 799-809.	2.4	68
44	Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1390-1401.	2.4	21
45	A non-circulating pool of factor XI associated with glycosaminoglycans in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1449-1460.	3.8	9
46	Modeling the effect of blood vessel bifurcation ratio on occlusive thrombus formation. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2019, 22, 972-980.	1.6	7
47	Identification, Quantification, and System Analysis of Protein N-ε Lysine Methylation in Anucleate Blood Platelets. <i>Proteomics</i> , 2019, 19, e1900001.	2.2	7
48	Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death. <i>Blood Advances</i> , 2019, 3, 658-669.	5.2	50
49	Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice. <i>Blood Advances</i> , 2019, 3, 3080-3091.	5.2	22
50	Bleeding TAPs out. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 247-249.	3.8	0
51	Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. <i>Platelets</i> , 2019, 30, 126-135.	2.3	27
52	Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?. <i>Platelets</i> , 2019, 30, 796-798.	2.3	11
53	The role of coagulation and platelets in colon cancer-associated thrombosis. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 316, C264-C273.	4.6	48
54	Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function. <i>Blood</i> , 2019, 134, 2074-2074.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo. <i>Blood</i> , 2019, 134, 3632-3632.	1.4	0
56	TRPing out Platelet Calcium. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 285-286.	2.4	5
57	Plasma contact factors as therapeutic targets. <i>Blood Reviews</i> , 2018, 32, 433-448.	5.7	50
58	Regulation of immune cell signaling by activated protein C. <i>Journal of Leukocyte Biology</i> , 2018, 103, 1197-1203.	3.3	14
59	Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug. <i>Platelets</i> , 2018, 29, 773-778.	2.3	12
60	A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. <i>Scientific Reports</i> , 2018, 8, 6564.	3.3	25
61	Potential of TRAP-6-induced platelet dense granule release by blockade of P2Y ₁₂ signaling with MRS2395. <i>Platelets</i> , 2018, 29, 383-394.	2.3	15
62	Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. <i>Pediatric Research</i> , 2018, 83, 693-701.	2.3	3
63	Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1748-1760.	2.4	30
64	Effect of Pneumatic Tubing System Transport on Platelet Apheresis Units. <i>Cardiovascular Engineering and Technology</i> , 2018, 9, 515-527.	1.6	3
65	Design and Utility of a Point-of-Care Microfluidic Platform to Assess Hematocrit and Blood Coagulation. <i>Cellular and Molecular Bioengineering</i> , 2018, 11, 519-529.	2.1	10
66	Platelet procoagulant phenotype is modulated by a p38-MK2 axis that regulates RTN4/Nogo proximal to the endoplasmic reticulum: utility of pathway analysis. <i>American Journal of Physiology - Cell Physiology</i> , 2018, 314, C603-C615.	4.6	18
67	The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. <i>Frontiers in Oncology</i> , 2018, 8, 78.	2.8	73
68	Platelet Mechanotransduction. <i>Annual Review of Biomedical Engineering</i> , 2018, 20, 253-275.	12.3	57
69	Polyphosphate nanoparticles on the platelet surface trigger contact system activation. <i>Blood</i> , 2017, 129, 1707-1717.	1.4	121
70	Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 312, C176-C189.	4.6	71
71	Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 835-847.	3.8	191
72	Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. <i>Journal of Biological Chemistry</i> , 2017, 292, 8616-8629.	3.4	84

#	ARTICLE	IF	CITATIONS
73	Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 312, C527-C536.	4.6	21
74	Utility of microfluidic devices to study the platelet-endothelium interface. <i>Platelets</i> , 2017, 28, 449-456.	2.3	10
75	Differential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin. <i>Annals of Biomedical Engineering</i> , 2017, 45, 1328-1340.	2.5	11
76	Ticagrelor breaks up the tumor-platelet party. <i>Blood</i> , 2017, 130, 1177-1178.	1.4	10
77	Utility and development of microfluidic platforms for platelet research. <i>Platelets</i> , 2017, 28, 425-426.	2.3	8
78	Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. <i>Convergent Science Physical Oncology</i> , 2017, 3, 023001.	2.6	38
79	Dynamics of Blood Flow and Thrombus Formation in a Multi-Bypass Microfluidic Ladder Network. <i>Cellular and Molecular Bioengineering</i> , 2017, 10, 16-29.	2.1	37
80	Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kinogen. <i>Thrombosis and Haemostasis</i> , 2017, 117, 671-681.	3.4	36
81	Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions. <i>Frontiers in Medicine</i> , 2017, 4, 232.	2.6	14
82	Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice. <i>PLoS ONE</i> , 2016, 11, e0152968.	2.5	49
83	Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI. <i>PLoS ONE</i> , 2016, 11, e0165172.	2.5	26
84	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. <i>Blood</i> , 2016, 128, 1870-1878.	1.4	34
85	Dimensional analysis and scaling relevant to flow models of thrombus formation: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 619-622.	3.8	27
86	Biorheology of Platelet Activation in the Bloodstream Distal to Thrombus Formation. <i>Cellular and Molecular Bioengineering</i> , 2016, 9, 496-508.	2.1	6
87	Heat shock protein 70 regulates platelet integrin activation, granule secretion and aggregation. <i>American Journal of Physiology - Cell Physiology</i> , 2016, 310, C568-C575.	4.6	31
88	The hemostatic role of factor XI. <i>Thrombosis Research</i> , 2016, 141, S8-S11.	1.7	60
89	Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 510-517.	2.4	28
90	Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. <i>American Journal of Physiology - Cell Physiology</i> , 2016, 310, C373-C380.	4.6	62

#	ARTICLE	IF	CITATIONS
91	E-WE Thrombin (ProCase) Inhibits Thrombin Mediated TAFI Activation and Accelerates TPA-Induced Thrombolysis. <i>Blood</i> , 2016, 128, 1390-1390.	1.4	0
92	Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding. <i>Blood</i> , 2016, 128, 4922-4922.	1.4	2
93	Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization. <i>Blood</i> , 2015, 125, 2995-3005.	1.4	42
94	Critical Behavior of Subcellular Density Organization During Neutrophil Activation and Migration. <i>Cellular and Molecular Bioengineering</i> , 2015, 8, 543-552.	2.1	1
95	Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. <i>Blood</i> , 2015, 125, 1488-1496.	1.4	51
96	A physical sciences network characterization of circulating tumor cell aggregate transport. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C792-C802.	4.6	54
97	Effect of Ionizing Radiation on the Physical Biology of Head and Neck Squamous Cell Carcinoma Cells. <i>Cellular and Molecular Bioengineering</i> , 2015, 8, 517-525.	2.1	8
98	The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C229-C236.	4.6	29
99	A theme series on Physical Biology in Cancer in AJP-Cell. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 306, C77-C77.	4.6	0
100	CXCR7 expression disrupts endothelial cell homeostasis and causes ligand-dependent invasion. <i>Cell Adhesion and Migration</i> , 2014, 8, 165-176.	2.7	8
101	Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system. <i>Pediatric Research</i> , 2014, 76, 230-237.	2.3	48
102	Network signatures of nuclear and cytoplasmic density alterations in a model of pre and postmetastatic colorectal cancer. <i>Journal of Biomedical Optics</i> , 2014, 19, 016016.	2.6	20
103	Measurement Science in the Circulatory System. <i>Cellular and Molecular Bioengineering</i> , 2014, 7, 1-14.	2.1	23
104	Factor XII inhibition reduces thrombus formation in a primate thrombosis model. <i>Blood</i> , 2014, 123, 1739-1746.	1.4	187
105	Development of a Method to Quantify Platelet Adhesion and Aggregation Under Static Conditions. <i>Cellular and Molecular Bioengineering</i> , 2014, 7, 285-290.	2.1	8
106	Rho GTPases in platelet function. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 35-46.	3.8	146
107	Microfluidics and Coagulation Biology. <i>Annual Review of Biomedical Engineering</i> , 2013, 15, 283-303.	12.3	110
108	Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1341-1352.	3.8	76

#	ARTICLE	IF	CITATIONS
109	The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 305, C519-C528.	4.6	41
110	Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an <i>in vitro</i> model of circulating tissue factor. <i>Physical Biology</i> , 2013, 10, 036003.	1.8	9
111	p21 Activated Kinase Signaling Coordinates Glycoprotein Receptor VI-Mediated Platelet Aggregation, Lamellipodia Formation, and Aggregate Stability Under Shear. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1544-1551.	2.4	34
112	Rac and Cdc42 team up for platelets. <i>Blood</i> , 2013, 122, 3096-3097.	1.4	9
113	Development Of a Novel Method To Assess Neonatal Platelet Function. <i>Blood</i> , 2013, 122, 4740-4740.	1.4	0
114	Regulation of the mTOR-Rac1 axis in platelet function. <i>Small GTPases</i> , 2012, 3, 67-70.	1.6	15
115	Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. <i>Blood</i> , 2012, 119, 4762-4768.	1.4	86
116	Antibodies to Human Factor XII with Antithrombotic Properties. <i>Blood</i> , 2012, 120, 1106-1106.	1.4	2
117	FXII Promotes Coagulation in a FXI and FIX Independent Manner. <i>Blood</i> , 2012, 120, 3362-3362.	1.4	1
118	Development of Coagulation Factor Probes for the Identification of Procoagulant Circulating Tumor Cells. <i>Blood</i> , 2012, 120, 634-634.	1.4	1
119	Exogenous modification of platelet membranes with the omega-3 fatty acids DHA and EPA impairs thrombogenesis. <i>FASEB Journal</i> , 2012, 26, 1016.5.	0.5	0
120	p21-Activated Kinases Regulate Directional Migration and Cytoskeletal Organization in Human Neutrophils. <i>Blood</i> , 2012, 120, 834-834.	1.4	0
121	S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. <i>Blood</i> , 2011, 118, 3129-3136.	1.4	112
122	Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. <i>Journal of Leukocyte Biology</i> , 2011, 90, 923-927.	3.3	24
123	The role of carrier number on the procoagulant activity of tissue factor in blood and plasma. <i>Physical Biology</i> , 2011, 8, 066005.	1.8	14
124	Coagulation Factors XIa and XIIIa Modulate Neutrophil Elastase Release,. <i>Blood</i> , 2011, 118, 3220-3220.	1.4	0
125	Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates. <i>Blood</i> , 2011, 118, 1173-1173.	1.4	1
126	Spatial Separation of TF-Carriers Modulates Procoagulant Activity of Circulating TF. <i>Blood</i> , 2011, 118, 2265-2265.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Rational Design of an Ex Vivo Model of Thrombosis. Cellular and Molecular Bioengineering, 2010, 3, 187-189.	2.1	12
128	Laminin promotes coagulation and thrombus formation in a factor XIII-dependent manner. Journal of Thrombosis and Haemostasis, 2010, 8, 1295-1301.	3.8	56
129	A role for factor XIIIa-mediated factor XI activation in thrombus formation in vivo. Blood, 2010, 116, 3981-3989.	1.4	227
130	Factor XI Inhibitor Antibody Treatment Improves Survival In a Murine Polymicrobial Sepsis Model. Blood, 2010, 116, 820-820.	1.4	0
131	Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood, 2009, 113, 936-944.	1.4	182
132	Identification of a novel, actin-rich structure, the actin nodule, in the early stages of platelet spreading. Journal of Thrombosis and Haemostasis, 2008, 6, 1944-1952.	3.8	47
133	Capture of Flowing Endothelial Cells Using Surface-Immobilized Anti-Kinase Insert Domain Receptor Antibody. Tissue Engineering - Part C: Methods, 2008, 14, 97-105.	2.1	59
134	Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood, 2007, 109, 3733-3740.	1.4	49
135	MyosinIIa contractility is required for maintenance of platelet structure during spreading on collagen and contributes to thrombus stability. Journal of Thrombosis and Haemostasis, 2007, 5, 2136-2145.	3.8	55
136	von Willebrand factor mediates platelet spreading through glycoprotein Ib and alphaIIb beta3 in the presence of botrocetin and ristocetin, respectively. Journal of Thrombosis and Haemostasis, 2006, 4, 1367-1378.	3.8	53
137	The Leech Product Saratin Is a Potent Inhibitor of Both VWF and Integrin $\alpha 2 \beta 1$ Binding to Collagen.. Blood, 2006, 108, 3928-3928.	1.4	0
138	Rac1 Is Essential for Platelet Lamellipodia Formation and Aggregate Stability under Flow. Journal of Biological Chemistry, 2005, 280, 39474-39484.	3.4	196
139	GPVI and integrin alphaIIb beta3 signaling in platelets. Journal of Thrombosis and Haemostasis, 2005, 3, 1752-1762.	3.8	374
140	Preferential binding of platelets to monocytes over neutrophils under flow. Biochemical and Biophysical Research Communications, 2005, 329, 345-355.	2.1	42
141	Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis. , 2004, 93, 21-34.		6
142	Evaluation of the role of platelet integrins in fibronectin-dependent spreading and adhesion. Journal of Thrombosis and Haemostasis, 2004, 2, 1823-1833.	3.8	81
143	Single Molecule Characterization of P-selectin/Ligand Binding. Journal of Biological Chemistry, 2003, 278, 10556-10561.	3.4	167
144	Exogenous eosinophil activation converts PSGL-1-dependent binding to CD18-dependent stable adhesion to platelets in shear flow. American Journal of Physiology - Cell Physiology, 2003, 284, C1223-C1234.	4.6	28

#	ARTICLE	IF	CITATIONS
145	Fluid Shear Regulates the Kinetics and Molecular Mechanisms of Activation-Dependent Platelet Binding to Colon Carcinoma Cells. <i>Biophysical Journal</i> , 2002, 83, 836-848.	0.5	58
146	Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. <i>Blood</i> , 2000, 96, 1789-1797.	1.4	196